Comparison of two intravenous methylprednisolone regimens for patients with moderate to severe and active Graves’ ophthalmopathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006848

Enrollment

Unknown

Registered

2015-07-31

Start date

2011-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' ophthalmopathy

Interventions

Two groups:Two doses of MP monthly for 3 months

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. patients with moderate to severe and active GO; 2. Patients should not have received any immunosuppressives therapy, orbital radiotherapy or surgery; 3. They may be hyperthyroid or hypothyroid when enrolling, but thyroid status have to be restored to normal within 2~4 weeks by anti-hyperthyroid drugs or levothyroxine with adjustment medication.

Exclusion criteria

Exclusion criteria: 1. Contraindications to GCs: active or unexplained gastric disease, active liver disease, a history of pulmonary tuberculosis, heart arrhythmias, uncontrolled hypertension, uncontrolled diabetes mellitus, glaucoma; 2. Having received iv. MP; 3. With symptoms and signs caused by other eye diseases; 4. Recurrent GO; 5. Dysthyroid optic neuropathy (DON).

Design outcomes

Primary

Measure	Time frame
Ophthalmologic examination;maxT2RTs and maxAreas;	—

Contacts

Public ContactHE Yebing

ybhe@tjh.tjmu.edu.cn+86 13429866675

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026